Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

7.370 -0.040 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences Inc

< Previous 1 2 3 4 5 6 7 Next >
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Kezar Life Sciences: Q1 Earnings Insights
Via Benzinga
Kezar Life Sciences to Participate in the Jefferies Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
Via Benzinga
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Why Kezar Life Sciences Shares Are Volatile After Hours
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher in Monday's after-hours session after the company announced that it has received clearance of its Investigational New Drug (IND)... 
Via Benzinga
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.